Main navigation
  • Investering
    • Beste Nettmegler
      • eToro Anmeldelse
      • Nordnet Anmeldelse
      • Plus500 Anmeldelse
    • Investering For Nybegynnere
      • Investere Penger
    • Investere i Eiendom
    • Passiv Inntekt
    • Tjen Penger på Nett
    • Råvarer
      • Investere i Gull
      • Investere i Olje
      • Investere i Sølv
    • ETF
    • Alle Artikler Om Investering
  • Aksjer
    • Kjøpe Aksjer
      • Anbefalte Aksjer 2021
      • Amerikanske Aksjer
      • Norske Aksjer
      • Grønne Aksjer
      • Defensive Aksjer
      • Volatile Aksjer
      • Laks Aksjer
      • Shipping Aksjer
    • Aksjetips 2021
      • Pfizer Aksjer
      • Moderna Aksjer
      • Tesla Aksjer
      • Apple Aksjer
      • Google Aksjer
      • Telenor Aksjer
      • Amazon Aksjer
      • Nintendo Aksjer
      • Zoom Aksjer
      • Equinor Aksjer
      • Hydro Aksjer
      • Nordea Aksjer
      • Yara Aksjer
      • Tomra Aksjer
      • Vaccibody Aksjer
    • Aksjeinvesteringer
      • Bygge en Aksjeportefølje
      • Hva er Kurtasje?
      • Hvordan Beregne Avkastning?
      • Finn din Aksjestrategi
    • Aksjer For Nybegynnere
    • Utbytteaksjer
    • Beste Aksje App
      • eToro Appen
    • Indeksfond
      • MSCI World Indeks
      • S&P 500 Indeks
      • Nasdaq Indeks
      • Dow Jones Indeks
      • FTSE 100 Indeks
      • Dax Indeks
      • Oslo Børs Hovedindeks
      • Vix Indeks
      • Nikkei 225 Indeks
    • Aksjefond
    • Alle Artikler Om Aksjer
  • Kryptovaluta
    • Alt om Kryptovaluta
    • Topp 16 Kryptovaluta
      • Kjøpe Polkadot [DOT]
      • Kjøpe Bitcoin [BTC]
      • Kjøp Bitcoin Cash [BCH]
      • Kjøp Ripple [XRP]
      • Kjøp Ethereum [ETH]
      • Kjøp NEO [NEO]
      • Kjøp Litecoin [LTC]
      • Kjøp TRON [TRX]
      • Kjøp IOTA [MIOTA]
      • Kjøp Tezos [XTZ]
      • Kjøp Dash [DASH]
      • Kjøp Cardano [ADA]
      • Kjøp Zcash [ZEC]
      • Kjøp Stellar [XLM]
      • Kjøp EOS Coin [EOS]
      • Kjøp Binance Coin [BNB]
    • Kryptovaluta Kurser
      • Bitcoin Kurs
      • Ethereum Kurs
      • Ripple Kurs
      • Tether Kurs
      • Litecoin Kurs
      • Bitcoin Cash Kurs
      • Cardano Kurs
      • Polkadot Kurs
      • Binance Coin Kurs
      • Stellar Kurs
      • ChainLink Kurs
      • USD Coin Kurs
      • Wrapped Bitcoin Kurs
      • Bitcoin SV Kurs
      • Monero Kurs
      • EOS Kurs
      • Tron Kurs
      • NEO Kurs
      • NEM Kurs
      • Tezos Kurs
      • Crypto Coin Kurs
      • VeChain Kurs
      • Uniswap Kurs
      • Cosmos Kurs
      • Aave Kurs
      • UNUS SED LEO Kurs
      • Dash Kurs
      • IOTA Kurs
      • Zcash Kurs
      • Revain Kurs
      • Ontology Kurs
    • Kjøp Bitcoin
    • Bitcoin Aksje
    • Bitcoin Trading
      • Bitcoin Exchange
      • eToro Anmeldelse
      • MiraiEx Anmeldelse
      • Coinbase Anmeldelse
      • Binance Anmeldelse
    • Bitcoin Wallet
    • Beste Bitcoin Plattform
    • Krypto-roboter
      • Bitcoin Era
      • Bitcoin Code
      • Bitcoin Profit
      • Bitcoin Gemini
      • Bitcoin Compass
      • Bitcoin Champion
      • Bitcoin Supersplit
      • Bitcoin Compass
      • Bitcoin Digital
      • Bitcoin Prime
      • Bitcoin Up
      • Bitcoin Bank
    • Alle Artikler Om Kryptovaluta
  • Trading
    • Beste Trading Plattform
      • eToro
      • SaxoTraderGo
      • Skilling
      • Plus500
      • Avatrade
      • ETX Capital
    • Beste Trading App
      • eToro Appen
    • Daytrading
    • Copytrading
    • Swing Trading
    • Forex Trading
      • Forex Broker
      • Handle Valuta
      • Valuta Trading Tips
    • CFD-handel
    • Shorting
    • Gearing
    • Alle Artikler Om Trading
✕

Johnson & Johnson, Pfizer, and Merck Lost $3.5B in Combined YTD Revenue

av Jastra Kranjec  Sist oppdatert: 25. november, 2020

The coronavirus pandemic put enormous pressure on the healthcare industry, forcing pharmaceutical giants to roll out clinical trials for a COVID-19 vaccine at breakneck speed.

At the same time, significant changes in demand, research and development processes, and regulation revisions amid the coronavirus crisis cut down revenues of the biggest players in the market and slowed down the growth of the entire pharmaceutical industry.

According to data presented by Aksje Bloggen, Johnson & Johnson, Pfizer and Merck, as the three leading pharma companies by sales, lost $3.5bn in combined YTD revenue.

Pfizer Revenues Dropped by $3B YTD, The Biggest Drop Among Top Three Companies

With over $80bn in annual revenue, around $30bn more than the next ranked company, Pfizer, Johnson & Johnson represents the world’s largest pharmaceutical company. However, the earnings report of the US multinational corporation revealed this figure is expected to drop amid the COVID-19 crisis.

After a steady growth between January and March, Johnson & Johnson’s revenue dropped by 10.8% YoY to $18.3bn in the second quarter of the year. The Group’s Q2 2020 results also showed consumer health sales fell 7% to $3.3bn, while pharmaceutical division revenues increased 2.1% to $10.75bn. Medical device sales tumbled 34% to $4.3 billion, as the coronavirus pandemic triggered postponements and cancellations of non-emergency surgeries.

Although the company recovered after the initial impact of the COVID-19 crisis, with sales growing by 1.7% to $21.1bn the third quarter, statistics show Johnson & Johnson`s revenue for the nine months dropped by $1.1bn.

As the second-largest pharma company by revenue, Pfizer has taken the hardest financial among the top three companies. Statistics indicate the revenue of the US pharma giant dropped by 7% to $12.5bn in the first months of 2020. The negative trend continued in the second quarter, with revenue falling to $11.8bn, a 9% decrease YoY.

Third-quarter sales dropped by $500 million, or 4%, due to COVID-19, primarily driven by lower demand for certain products in China and disruptions to wellness visits for patients in the United States, negatively impacting prescribing patterns for specific products. Statistics show Pfizer’s revenue for the nine months of 2020 amounted to $35.9bn, a $3bn drop year-over-year.

Merck, as the third-largest pharma giant by sales, was the only company on this list whose revenue slightly increased in the nine months, mostly driven by strong performance in the first quarter of 2020.

After an 11% growth YoY between January and March, Merck’s revenue fell by 8% to $10.9bn in the second quarter. Third-quarter worldwide sales hit $12.6bn, an increase of 1% YoY. Statistics show the US pharmaceutical giant generated $35.5bn in the nine months of 2020, a $600 million increase compared to the same period a year ago.

Johnson & Johnson Stocks Rise, Merck’s Market Cap Dropped by $29bn YTD

Besides sizeable revenue drops due to the Covid-19 pandemic, some of the leading companies responsible for the research, development, and production of medications also witnessed significant market cap drops this year.

Statistics show that Merck`s market cap plunged by almost $29bn in 2020, the biggest drop among the top three companies. In December 2019, the company’s combined value of shares stood at $230.9bn. However, this figure fell to $194bn after a stock market crash in March. The following months witnessed a recovery, with the market cap peaking at $216.4bn in September. However, this figure slumped to $202bn last week, a 12% YTD decrease.

Pfizer’s market cap stood at $201.8bn in the third week of November, almost $15bn drop since the beginning of the year.

The Yahoo Finance data showed Johnson & Johnson is the only company among the top three pharma giants whose market cap increased amid the COVID-19 outbreak. After a sharp fall to $345.1bn in March, the market cap of the world’s largest pharma company rose to $370.1bn in the second quarter of 2020 and continued growing. Last week, Johnson & Johnson market cap stood at $385.3bn, a $1.3bn increase since the beginning of 2020.

Om Jastra Kranjec

Jastra is an editor, writer, and PR specialist with years of experience in the news, research, and report writing. Over the years, she has worked in different fields of journalism and public relations, including politics, economy, and financial markets.

Reader Interactions

Kommentarer

Legg igjen en kommentar Avbryt svar

Din e-postadresse vil ikke bli publisert. Obligatoriske felt er merket med *

Feltet er påkrævet.

Feltet er påkrævet.Du skal venligst indtaste en gyldig e-mailadresse.

Feltet er påkrævet.

Footer After Content

Invester i nyhetsbrevet!

Du kan melde deg på nyhetsbrevet vårt på Aksjebloggen, så skriver jeg til deg når det er nye oppdateringer på bloggen.

Du melder deg på nyhetsbrevet vårt, og gir Aksjebloggen tillatelse til å sende deg nyhetsbrev med markedsføingsmateriale.

Footer

Aksjebloggen
Finixio Ltd
3 Lower Thames Str, St Magnus House
London EC3R 6HE
United Kingdom
+44 (0)203 146 8423

Informasjon

  • Artikler
  • Disclaimer
  • Personvernerklæring
  • Bruk av informasjonskapsler (cookies)
  • Kontakt
  • Om Oss

Footer Disclaimer

Disclaimer

Note that the content on this site should not be considered investment advice. Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site.

© 2021 Aksjebloggen. Få mer ut av pengene dine. Alle rettigheter forbeholdes.
✕
✕